Article Text

Download PDFPDF

04132 Heme-driven pathologies in the context of infections: from TLR4 signaling to COVID-19
  1. Diana Imhof
  1. Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, Bonn, Germany

Abstract

Heme is not only a prosthetic group of hemoproteins, but also a potent effector molecule. This regulatory heme can bind to short nonapeptide sequences, i.e. heme-regulatory motifs (HRMs), on the protein surface. We studied >300 HRMs in detail employing peptides and proteins as well as a plethora of spectroscopic and bioinformatics methods. Apart from knowledge acquired for the physiological role of transient heme binding to proteins, its pathophysiological impact is still not completely understood. However, a considerable amount of heme is released under hemolytic conditions and causes pathological states such as thrombosis. On the other hand, the SARS-CoV2-triggered respiratory tract disease COVID-19 has been shown to lead to serious changes in clinical biomarkers like hemoglobin and interleukins, parameters, which are also altered during hemolysis. With various computational-experimental basic and advanced studies, we aimed at analyzing a potential link between heme-related and COVID-19 pathophysiologies. We performed a detailed analysis of the common pathways induced by heme and SARS-CoV-2 by superimposition of knowledge graphs covering heme biology (Heme-KG) and COVID-19 pathophysiology. Thereby, focus was laid on inflammatory pathways and distinct biomarkers as the linking elements. In a subsequent approach, four COVID-19-related proteins, the host cell proteins ACE2 and TMPRSS2 as well as the viral protein 7a and protein S as well as HRM-peptides derived thereof, were experimentally and computationally analyzed as potential heme-binding proteins. The results contribute to our understanding of the progression heme-related diseases in the context of infections in patients with different clinical backgrounds and may allow for a more individual diagnosis and therapy in the future.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.